SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-24-002961
Filing Date
2024-05-03
Accepted
2024-05-03 16:26:18
Documents
15
Period of Report
2024-04-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm   iXBRL 8-K 50131
2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION O cns_0301.htm EX-3.1 1763
3 CNS PHARMACEUTICALS, INC. 2020 EQUITY PLAN (AS AMENDED APRIL 30, 2024) cns_1001.htm EX-10.1 98425
  Complete submission text file 0001683168-24-002961.txt   349975

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cnsp-20240430.xsd EX-101.SCH 3018
5 XBRL LABEL FILE cnsp-20240430_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE cnsp-20240430_pre.xml EX-101.PRE 22361
18 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3919
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 24913567
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)